CN108884137B - 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途 - Google Patents

肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途 Download PDF

Info

Publication number
CN108884137B
CN108884137B CN201780022355.2A CN201780022355A CN108884137B CN 108884137 B CN108884137 B CN 108884137B CN 201780022355 A CN201780022355 A CN 201780022355A CN 108884137 B CN108884137 B CN 108884137B
Authority
CN
China
Prior art keywords
peptide
dbd
mutant
cancer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780022355.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108884137A (zh
Inventor
V.洛特尔
M.奥仁
P.塔尔
S.艾真伯格
A.本-施蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN108884137A publication Critical patent/CN108884137A/zh
Application granted granted Critical
Publication of CN108884137B publication Critical patent/CN108884137B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780022355.2A 2016-02-04 2017-02-03 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途 Expired - Fee Related CN108884137B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291003P 2016-02-04 2016-02-04
US62/291,003 2016-02-04
PCT/IL2017/050132 WO2017134671A1 (en) 2016-02-04 2017-02-03 Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53

Publications (2)

Publication Number Publication Date
CN108884137A CN108884137A (zh) 2018-11-23
CN108884137B true CN108884137B (zh) 2022-04-05

Family

ID=58108701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780022355.2A Expired - Fee Related CN108884137B (zh) 2016-02-04 2017-02-03 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途

Country Status (8)

Country Link
US (1) US11230578B2 (enExample)
EP (1) EP3411390A1 (enExample)
JP (2) JP7072508B2 (enExample)
CN (1) CN108884137B (enExample)
AU (1) AU2017214733B2 (enExample)
CA (1) CA3012302A1 (enExample)
RU (1) RU2762089C2 (enExample)
WO (1) WO2017134671A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015019318A1 (en) 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
CN108884137B (zh) 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
WO2021186431A1 (en) 2020-03-16 2021-09-23 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
CN112578106B (zh) * 2020-04-13 2022-04-22 南京大学 一种纳米孔道单分子蛋白质测序仪
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
WO2015019318A1 (en) * 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5294605A (en) * 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5969120A (en) 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5711376A (en) 1995-12-07 1998-01-27 Marathon Oil Company Hydraulic fracturing process
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
EP0989136A4 (en) 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk PEPTIDES WITH CYCLIC STRUCTURES THAT CAN RECOVER THE ACTIVITY OF MUTED P53 PROTEINS.
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2002072600A2 (en) 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
EP1472276A4 (en) 2001-02-28 2007-05-09 Keith M Skubitz PEPTIDES OF SMALL SIZE CAPACITY TO MODULATE THE FUNCTION OF THE MEMBERS OF THE FAMILY OF CD66 (CEACAM)
US20070105778A1 (en) 2002-01-23 2007-05-10 El-Gewely Mohamed R Methods of screening molecular libraries and active molecules identified thereby
US7361747B2 (en) 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
WO2007149062A2 (en) 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
GB0514538D0 (en) * 2005-07-14 2005-08-24 Ludwig Inst Cancer Res Variant polypeptide and screening assay
EP2268658B1 (en) 2008-03-13 2015-12-09 Universita'Degli Studi di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8287845B2 (en) 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
CN101805738B (zh) * 2009-11-12 2012-03-21 昆明理工大学 早老综合征所致ALT肿瘤的特有p53突变蛋白-p53N236S及其应用
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CN108884137B (zh) 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329493A (zh) * 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
WO2015019318A1 (en) * 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A small peptide derived from p53 linker region can resume the apoptotic activity of p53 by sequestering iASPP with p53";Shi Qiu et al.;《Cancer Letters》;20151231;第356卷;第910-917页 *
"An All-D Amino Acid Peptide Model of R1(IV)531-543 from Type IV Collagen Binds the α3β1 Integrin and Mediates Tumor Cell Adhesion, Spreading, and Motility";Changfen Li et al.;《Biochemistry》;19971231;第36卷(第49期);第15404-15410页 *
"残基突变对P53-DNA结合域肽段构象影响的分子动力学模拟";许朝莹 等;《物理化学学报》;20120418;第28卷(第7期);第1665-1675页 *

Also Published As

Publication number Publication date
US20190048053A1 (en) 2019-02-14
CA3012302A1 (en) 2017-08-10
RU2762089C2 (ru) 2021-12-15
RU2018131120A (ru) 2020-03-05
AU2017214733B2 (en) 2022-09-29
RU2018131120A3 (enExample) 2020-06-25
CN108884137A (zh) 2018-11-23
AU2017214733A1 (en) 2018-09-06
JP2019512004A (ja) 2019-05-09
WO2017134671A1 (en) 2017-08-10
EP3411390A1 (en) 2018-12-12
JP2022112518A (ja) 2022-08-02
JP7072508B2 (ja) 2022-05-20
US11230578B2 (en) 2022-01-25

Similar Documents

Publication Publication Date Title
CN108884137B (zh) 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
ES2795982T3 (es) Péptidos capaces de reactivar mutantes de p53
KR20160013058A (ko) 암의 치료를 위한 방법 및 조성물
EP1996612A1 (en) Compositions for treatment of cancer
US11376305B2 (en) Compositions and methods for regulating blood pressure
CN111655277B (zh) Atf5肽变体及其用途
CN114026114B (zh) 用于治疗再灌注损伤的bnip3肽
US20150202248A1 (en) E2f as a target of hormone refractory prostate cancer
US9683025B2 (en) Methods and compositions for treating cancer and inflammatory diseases
US10316077B2 (en) Cell-penetrating ATF5 polypeptides and uses thereof
US20190030126A1 (en) Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors
US20220251159A1 (en) Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
US20140005119A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
JP2023524558A (ja) Ｐｃｎａ相互作用モチーフを含むペプチドの固形癌の治療における使用
HK1219742B (en) Peptides capable of reactivating p53 mutants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220405